Published December 5, 2022
- CADTH recommends that Zeposia be reimbursed by public drug plans for the treatment of ulcerative colitis (UC) if certain conditions are met.
- Zeposia should be covered for a similar patient population and in a similar way to other drugs currently reimbursed by public drug plans for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, a loss of response, or intolerance to conventional therapy or a biologic agent.
- Zeposia should only be reimbursed if it is prescribed by a physician experienced in treating UC, the dosage does not exceed 0.92 mg daily, and it is not used in combination with biologics or Janus kinase inhibitors for UC. Zeposia should not cost more than other biologic therapies or targeted synthetic drugs covered by the public drug plans for the treatment of moderately to severely active UC.